Log in to your Inderes Free account to see all free content on this page.
BioPorto
0.93 DKK
-1.27 %
Less than 1K followers
BIOPOR
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-1.27 %
+2.42 %
-8.09 %
-8.63 %
-26.84 %
-35.30 %
-38.04 %
-78.54 %
-60.88 %
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read moreMarket cap
461.44M DKK
Turnover
39.72K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Latest research
Latest analysis report
Released: 01.04.2026
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
24.4.
2026
General meeting '26
21.5.
2026
Interim report Q1'26
20.8.
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
ShowingAll content types
Grant of Warrants
Major Shareholder Announcement
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
